Spokane, WA — Jubilant HollisterStier, a wholly owned subsidiary of ultimate parent company Jubilant Pharmova Limited, announces $92M investment to expand sterile injectable manufacturing capacity at its site in Spokane, WA. This investment is being made to set up a high-speed 400 vials a minute injectable fill line with isolator technology, which will enhance the Spokane facility’s capacity by 50%. This expansion will also include two 300 sq. foot lyophilizers. This expansion will be spread over 50,000 sq. feet at the Spokane facility and will be commercially operational by the end of 2024. Jubilant HollisterStier has already begun filling new roles to support this expansion and will continue to recruit additional talent.
“We are excited to expand our sterile injectable and vaccine manufacturing capacity and meet the increasing demand from our customers.” said Amit Arora, President Jubilant HollisterStier. “We are pleased to announce the planned expansion of the sterile injectable manufacturing capacity at this critical juncture. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic and are prepared for a potential future pandemic response. This expansion will also help us meet high demand from our global Specialty Pharmaceutical customers, with whom the company has established strong relationships” stated Pramod Yadav, CEO Jubilant Pharma Limited.
About Jubilant HollisterStier
Jubilant HollisterStier LLC, a part of Jubilant Pharma Limited, is a leading integrated contract manufacturer of sterile injectables, ophthalmics, otics, sterile and non-sterile topicals and liquids. With facilities in North America, Jubilant HollisterStier provides specialized manufacturing for the pharmaceutical and biopharmaceutical industries. Services include a full-range of support to streamline the manufacturing process, from process qualifications through commercial release.
About Jubilant Pharma Limited
Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non Sterile products through six US FDA approved manufacturing facilities in the US, Canada and India and a network of 49 radiopharmacies in the US. The Company has a team of around 5,200 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.